Released Aug 8, 2011, before the open
10-Q filed Aug 8, 2011, 39 days after period end · 0001144204-11-044353
Q2 2011 · 10-Q
Revenue$764.00K$764.00K −33.0% vs Q2 2010no prior Q1 2011 on file
Net Income-$13.69M-$13.69M N/M vs Q2 2010N/M vs Q1 2011
EPS Diluted-$0.16-$0.16 N/M vs Q2 2010N/M vs Q1 2011
Gross Profit-$4,750,000N/M
Operating Income-$13,868,000N/M
Operating Cash Flowderived-$4,823,000—
Free Cash Flowderived-$6,235,000—
Margins · derived
Gross margin-621.7%−675.5 pt vs Q2 2010
Operating margin-1815.2%−925.6 pt vs Q2 2010
Net margin-1791.8%−911.7 pt vs Q2 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2011 | Q2 2010 |
|---|---|---|
| Revenue | $764.00K | $1.14M |
| Net Income | -$13.69M | -$10.04M |
| EPS Diluted | -$0.16 | $0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR